References
- Zinkernagel RM. Immunity, immunopathology and vaccines against HIV? Vaccine20, 1913–1917 (2002).
- Benhar I. Biotechnological applications of phage and cell display. Biotechnol. Adv.19, 1–33 (2004).
- Arap W, Kolonin MG, Trepel M et al. Steps toward mapping the human vasculature by phage display. Nature Med.8(2), 121–127 (2002).
- Manoutcharian K, Gevorkian G, Cano A, Almagro JC. Phage-displayed biomolecules as preventive and therapeutic agents. Curr. Pharmac. Biotech.2, 217–223 (2001).
- Clark JR, March JB. Bacterial viruses as human vaccines? Expert Rev. Vaccines3(4), 463–476 (2004).
- Fogelman I, Davey V, Ochs HD et al. Evaluation of CD4+ T-cell function in vivo in HIV-infected patients as measured by bacteriophage phi 174 immunization. J. Infect. Dis.182, 435–441 (2000).
- Thiel K. Old dogma, new tricks – 21st century phage therapy. Nature Biotech.22(1), 31–36 (2004).
- Krag DN, Fuller SP, Oligino L et al. Phage-displayed random peptide libraries in mice: toxicity after serial panning. Cancer Chemother. Pharmacol.50(4), 325–332 (2002).
- Manoutcharian K, Díaz-Orea A, Gevorkian G et al. Recombinant bacteriophage-based multiepitope vaccine against Taenia solium pig cysticercosis. Vet. Immunol. Immunopath.99, 11–24 (2004).
- Petrenko VA, Smith GP. Phage from landscape libraries as substitute antibodies. Prot. Engin.13(8), 589–592 (2000).
- Carrera MRA, Kaufmann GF, Mee JM et al. Treating cocaine with viruses. Proc. Natl Acad. Sci. USA101(28), 10416–10421 (2004).
Website
- APALEXO Biotechnologie GmbH www.apalexo.com (Accessed January, 2005)